drugset / Trial / NCT04569188

Convalescent Plasma in COVID-19 Elderly Patients

NCT04569188

Phase 2 Completed 21 enrolled Azienda Socio Sanitaria Territoriale di Mantova
NaSingle-groupOpen-labelTreatment

Summary

The trend of the spread of the COVID-19 pandemic demonstrates in Lombardy, starting from 28.03.2020, a slowdown in the exponential phase of infections and the probable reaching of a plateau phase. However, a marked increase in infections was observed in the so-called "protected structures" such as nursing homes (RSA), both in health staff and in the residents of such facilities. The observed percentage of lethality, according to the more recent data provided by the National Institute of Health, is very high especially among residents. For these reasons, the city Hospital (ASST) of Mantua , already involved in the use of hyperimmune plasma as a therapy for COVID-19, designed this study in order to evaluate RSA patients and to identify the cases eligible for this treatment.

Timeline

Start
2020-05-15
Primary completion
2020-08-15
Completion
2020-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic Other

Indications